Login to Your Account

Active Biotech's Immunotherapy Anyara Is Down but Not Out

By Cormac Sheridan
Staff Writer

Wednesday, January 30, 2013
Shares in Active Biotech AB fell almost 13 percent Monday on news that its immunotherapy Anyara missed the primary endpoint of a Phase II/III trial in advanced renal cell cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription